Medical publications on HBV and HCV Coinfection
|
|
- Delphia Elliott
- 3 years ago
- Views:
Transcription
1 Recent advances of HBV and HCV co-infection 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師
2 Outline Epidemiology of HBV and HCV coinfection Clinical significance of HBV and HCV coinfection Interplay between HBV and HCV in coinfection Treatment HCV dominant coinfection HBV dominant coinfection Conclusions
3 HBV and HCV coinfection Definition: HBsAgantigenemiaand/or HBV viremia plus HCV viremia
4 HBV and HCV co-infection is not uncommon in HBV or HCV endemic area In areas where HBV or HCV is endemic, it is common to encounter patients infected with both viruses South East Asia Mediterranean region Prevalence 10-20% in patients with chronic hepatitis B 2-10% in anti-hcv-positive patients Crespo, et al. Am J Gastroenterol 1994 FattovichG, et al. J Infect Dis 1991 Gaeta GB, et al. J Hepatol2003
5 HBV-HCV HCV coinfection is frequently found in high-risk populations Similar transmission routes 66 Patients (%) Hemodialysis Organ Transplant patients Beta-thalassemia patients Injecting drug users HIV-positive patients Liu Z and HouJ. et al. IntJ Med Sci2006
6 Estimated prevalence rate of HBV-HCV HCV coinfection Worldwide, 350 million people with chronic HBV infection and an estimated 170 million people have chronic HCV infection. HBV-HCV coinfection is prevalent in area where HBV or HCV is endemic. Liu CJet al. HepatolInt2009
7 Clinical significance of HBV and HCV coinfection In most studies, Dually infected patients may have worse clinical outcomes than those with either virus mono-infection
8 Co-infection associated with a higher risk of cirrhosis or HCC Fibrosis score: Prevalence of cirrhosis: HCC: Repeatedly elevated ALT: B+C > C B+C > B B+C > C B+C > B B+C > C B+C > B B+C > B Sagnelli, et al. Infection 2004 Zarski, et al. J Hepatol 1998 Gaeta, et al. J Hepatol 2003 Kirk, et al. Hepatology 2004
9 Patients with HBV/HCV coinfection experience poor long-term outcomes A multicenter Italian (hospital-based cross-sectional) study Patients with HBV/HCV dual infection are at increased risk of cirrhosis compared with those with HBV or HCV monoinfection Patient with cirrhosis (%) 35% 30% 29% 25% 20% 15% 15% 10% Gaeta GB, et al. J Hepatol2003 5% 0% HBV only HBV-HCV
10 Influence and Interaction of HBV and HCV on the Risk of HCC Hospital-based cross-sectional study HCC No. (%) Controls No.(%) Relative Risk (95% C.I.) HBsAg(-) & Anti-HCV(-) 61 (12.5%) 267 (69.5%) 1.00 HBsAg(+)& Anti-HCV(-) 87 (68.0%) 104 (27.1%) 13.96( ) HBsAg(-) & Anti-HCV(+) 13 (10.1%) 8 (2.1%) 27.12( ) HBsAg(+) & Anti-HCV(+) 12(9.4%) 5 (1.3%) ( ) Total 128 (100%) 384 (100%) HBV and HCV have addictive effect on hepatic carcinogenesis Chuang WL, et al. Cancer 1992
11 Long-Term Outcome: Acute HCV Superinfection vs. CHB Alone (Hospital-based case-control study) (Age, Sex, HBeAg match) HCV on HBV HDV on HBV HBV alone Case No LC 20 (31.3%) 12 (18.7%) 11 (17.2%) HCC 6 (9.4%) 2 (3.1%) 3 (4.7%) LC HCV on HBV (P <0.0001) HDV on HBV HCC (P <0.039) HCV on HBV CHB alone HDV on HBV CHB alone Liaw YF, et al. Gastroenterology 2004
12 HBV-HCV HCV co-infected patients are at increased risk of HCC (Community-based cohort study) HCC risk is significantly higher in HBV-HCV co-infected patients than in those with mono-infection (p=0.030 and , respectively) B+C C B NBNC Huang YT, Chen CJ et al. J ClinOncol2011
13 Viral interference Mostly detectable HCV Viremia and low HBV DNA Sometimes high HBV DNA and low HCV RNA Cave: Mostly cross sectional studies Chu et al. J Gastroenterol Hepatol 2008 Crockett et al. Ann Clin Microbol and Antimicrobial 2005
14 Concurrent HBV and HCV coinfection HBV DNA positivity (%) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 54.0% P < % CHB Dual CHB and CHC A makred inhibition of HBV replication by HCV coinfection Sagnelli E, et al. Hepatology 2000
15 Chronic hepatitis B patients with and without HCV co-infection: HCV dominant Dai CY, et al. J. Gastroenterol. Hepatol. 2001
16 A suppressive effect of HCV on HBV viral load (Community-based cohort study) Viral load compared between groups with mono- and dual infection Huang YT, Chen CJ et al. J ClinOncol2011
17 Impact of HBV on HCV replication Detectable serum HCV RNA: In 41%~65% anti-hcv + and HBsAg+ In 90%~98 % anti-hcv + HCV RNA level lower in HBV DNA positive than in HBV DNA negative patients Wang, et al. J Gastroenterol 1999 Mathurin, et al. J Viral Hepatol 2000 Sagnelli, et al Hepatology 2000 Jardi, et al. Hepatolology 2001 Chu, et al. Scand J Gastroenterol 2004 Zarski, et al. J Hepatol1998
18 Concurrent HBV and HCV dual infection HCV RNA positivity (%) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 90.7% CHC P < % Dual CHC and CHB A significantly lower rate of HCV viremia among patients with chronic HBV and HCV dual infection Sagnelli E, et al. Hepatology 2000
19 Acute HBV Superinfection in Patients with Chronic Hepatitis C: HBV dominant HCV RNA positivity (%) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Sagnelli E, et al. Hepatology % CHC P < % CHC with acute HBV infection A marked inhibition of the HCV genome by HBV acute replication
20 Impact of HBV on HCV Impact of HBV on spontaneous HCV clearance Objective: factors associated with HCV clearance Study population: 203 spontaneously HCV-recovered subjects (HCV Ab+/RNA-) 293 chronically HCV-infected patients (HCV Ab+/RNA+) HIV co-infection negatively associated with HCV clearance (OR 0.37; ) HBV co-infection positively associated with HCV clearance (OR 5.0; ) Piasecki, et al. Hepatolology 2004
21 Concurrent HBV and HCV dual infection A much higher rate of spontaneous HCV clearance among HBV/HCV dually infected patients Dai CY, et al. GUT 2007
22 HBsAg-seropositivity seropositivity is associated with spontaneous HCV clearance A cohort of 106 patients of intravenous drug injection Exposure to HBV infection does not ensure spontaneous HCV clearance Van den Berg CH, el al. PLoSONE2011
23 Mini-summary Active HCV infection suppress HBV infection HBV could enhance spontaneous HCV clearance There exists in vivo reciprocal virus interaction between HBV and HCV infection Shih CM, et al Journal of Virology 1993 Schuttler Christian G, et al. J Hepatol 2002
24 Treatment of HBV/HCV coinfection All HCV RNA positive About 80-90% HCV dominant (HBeAg negative, low HBV DNA level) About 10-20% HBV dominant (HBeAgpositive, high HBV DNA level), usually in young children or teenager Practical goals for treatment Eradicate HCV Control HBV (ideally to eradicate)
25 Treatment of HBV/HCV coinfection: needed urgently, which virus is the target? 60% % 50% 48% 40% 30% 20% 10% 23% 14.5% 14.5% 0% Active HCV/Inactive HBV Active HCV/Active HBV Inactive HCV/Active HBV Inactive HCV/Inactive HBV Raimondo G et al. Hepatology 2006
26 Proposed strategies for the treatment of HBV/HCV hepatitis Possible regimens: Treat HCV as a priority by Peg-IFN/RBV Treat HBV as a priority by NUC and/or Peg-IFN Treat both: Combined Peg-IFN/RBV/NUC
27 Current treatment guidelines for HBV and HCV coinfection The dominant virus in HBV-HCV co-infected patients should be determined before treatment 1 HBV DNA levels are often low or undetectable and HCV is usually responsible for the activity of chronic hepatitis in most patients 2,3 HBV-HCV co-infected patients may be selected for antiviral treatment by the same criteria as those patients with HCV monoinfection McCaughanGW, et al. JGH CraxiA, et al. J Hepatol MarcellinP, et al. J Hepatol2009
28 Achieving an SVR may be considered equivalent to a cure for CHC
29 PEGSYS + ribavirin in patients with HCV/HBV or HCV alone study design (n=161) (n=160) (n=97) (n=64) (n=110) (n=50) Liu et al, Gastroenterology 2009
30 Similar SVR rates in HBV-HCV HCV co-infected compared with HCV monoinfected Asian patients HCV SVR(%) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% PEGASYS 180 μg/wk + RBV mg/d for 48 weeks 72% Liu CJ, et al. Gastroenterology % PEGASYS 180 μg/wk + RBV 800 mg/d for 24 weeks 77% 84% N= HCV GT1 HCV GT2/3 HCV GT1 HCV GT2/3 HBV-HCV co-infection HCV mono-infection ITT population
31 HBV viral load (low or intermediate level) does not affect HCV SVR Active HBV (intermediate level) Inactive HBV (low level)hbv DNA HBVDNA 10 4 ~10 5 copies/ml <10 4 copies/ml Case No. 40 (25%) 121 (75%) SVR 77.5% 76.9% Liu CJ, et al, Gastroenterology 2009
32 HCV SVR is durable in HBV-HCV HCV co-infected pts Median 4.6-year (range 1-5 years ) post-treatment follow-up Reappearance of HCV RNA in 6 pts(5 relapse, 1 re-infection) HCV SVR(%) 100% PEGASYS 180 μg/wk + RBV mg/d for 48 weeks 94% PEGASYS 180 μg/wk + RBV 800 mg/d for 24 weeks 100% 100% 98% 80% 60% 40% 20% 0% N= 78/83 55/55 86/86 39/40 HCV GT1 HCV GT2/3 HCV GT1 HCV GT2/3 HBV-HCV co-infection HCV mono-infection Yu ML, Hepatology 2013 (Epub)
33 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Virological response* to HBV: in paitents with detectable HBV DNA pre-treatment HBV VR*(%) 68 patients with HBV-HCV co-infection had detectable HBV DNA at baseline End-of-treatment 63% Liu CJ, et al, Gastroenterology % 6m post-treatment 58% 53% HCV GT1 HCV GT2/3 HCV GT1 HCV GT2/3 * HBV DNA <1,000 copies/ml at end of therapy or post-treatment
34 HBsAg clearance 6 months post-treatment treatment Total HCV GT 1 HCV GT 2/3 P EOT 19/161 (11.8%) 14/97 5/64 (11.8%) (14.4%) (7.8%) EOFU 18/161 (11.2%) 12/97 (12.4%) 6/64 (9.4%) Seroconversionto anti-hbs noted in 8 (44.4%) of the 18 cases at EOFU Liu CJ, et al, Gastroenterology 2009
35 Low pre-treatment HBsAg titer is associated with clearance of HBsAg 6 months post-treatment treatment Liu CJ, et al, Gastroenterology 2009
36 Baseline HBsAg level predicts HBsAg clearance 6 months post-treatment treatment By using ROC curve, 20 IU/mL was the best cut-off of serum HBsAglevel at baseline for predicting HBsAg clearance 6 months post-treatment Accuracy Sensitivity Specificity PPV NPV 91.2% 85.7% 84% 41.4% 97.8% The HBsAgclearance rate among the 30 patients with baseline serum HBsAg<20 IU/mL (40%, n=12)was significantly greater than among the 90 patients with baseline serum HBsAg >20 IU/mL (2.2%, n=2; P <0.05) Yu ML et al. J Infect Dis 2010
37 Around 30% of cumulative rate of sustained HBsAg seroclearance during 5Y F/U 48-wk PegIFN/RBV 24-wk PegIFN/RBV Yu ML, Hepatology2013 (Epub)
38 19 German ptswith chronic HBV/HCV coinfection (HBsAg and HCV RNA positive) 10 HCV GT1; 9 HCV GT 2/3 Baseline HBV DNA negative in 13 (68%) Peg-IFN alfa-2b and ribavirin for 48 weeks PotthoffA, et al. J Hepatol2008
39 HCV SVR rates in HBV-HCV HCV co-infected patients * GT2: n=4; GT3: n=5 PotthoffA, et al. J Hepatol2008
40 Reactivation of HBV? Releasing the enemy within
41 HBV reappearance in patients with undetectable serum HBV DNA pre-treatment Post-treatment HBV reappearance: 28/77 (36.4%) No significant hepatitis flare Dual Hepatitis C and B HCV GT1 HCV GT 2/3 HBV DNA Number (%) Baseline EOT EOFU (68.1%) 17 (56.7%) + 5 (10.6%) 7 (23.3%) + 6 (12.8%) 5 (16.7%) (8.5%) 1 (3.3%) HBV reappearance: increase of serum HBV DNA to >1,000 copies/ml post-treatment Liu CJ, et al, Gastroenterology 2009
42 German experience Potthoffet al. J Hepatol2008 HBV reappearance rate: 4/19 (21%)
43 Mini-Summary (1) HCV SVR in dually infected patients is the same as in HCV mono-infected patients SVR is also durable (~97%) HBV co-infection does not influence HCV SVR Active HBV Inactive HBV
44 Mini-Summary (2) HBV virological response was obtained in 53~58% of patients with dual HBVHCV infection Importantly, HBsAgclearance was observed in ~10% of dually infected patients at end of treatment and increased to about ~30% during 4.6-year follow-up However, about 33%of dually infected patients experienced reappearance of HBV DNA, but without significant hepatitis flare
45 Optimal treatment for HBV dominant dual infection? Further clinical trials are needed!
46 Combined IFN plus Lamivudine treatment in patients with HBeAg+ve, dual HBV and HCV chronic infection HCV SVR, EOT/EOFU HBV DNA negative, EOT/EOFU HBsAg loss HBeAg loss/ Anti-Hbe conversion 50%/50% 37.5%/12.5% 0% 37.5%/20% Marroneet al. J Hepatol2004
47 Conclusions HCV/HBV coinfection is prevalent in some parts of South- East Asia HBV endemic countries High risk populations include IDUs and HIV patients High risk of LC and HCC compared to either virus monoinfection HCV/HBV dually infected patients with HCV dominance should be treated with the same regimen as monoinfected HCV patients Comparable HCV SVR rates and HCV SVR durability in HCV/HBV dually infected patients as observed among those with HCV monoinfection Peg-IFN/RBV therapy may also result in an HBV virologic response Clearance of HBsAgis possible in a significant proportion of patients, especially in those with low baseline HBsAg level
Co-infected health-care workers
Co-infected health-care workers Y.Yazdanpanah Service Universitaire des Maladies Infectieuses et du Voyageur C.H. Tourcoing, Faculté de Médecine de Lille CNRS U362, Lille, France Co-infected health-care
More informationOptimising therapy in chronic hepatitis B: Switch or add treatment
Optimising therapy in chronic hepatitis B: Switch or add treatment Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University,Thailand NA + NA Percent with resistance
More informationLong-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B
Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Patrick Marcellin Viral Hepatitis Research Center Hôpital Beaujon, University of Paris France OBJECTIVES OF THERAPY IN CHRONIC
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationMolecular Diagnosis of Hepatitis B and Hepatitis D infections
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationCase Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationFocus on Transplantation: Treatment Post-transplant for HBV and HCV
Focus on Transplantation: Treatment Post-transplant for HBV and HCV The Viral Hepatitis Congress, Frankfurt, 09. September 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische Klinik I
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationBoehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
More informationNew IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
More informationHBV Treatment Guidelines. By: Prof.Dr. Abdelfatah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine
HBV Treatment Guidelines By: Prof.Dr. Abdelfatah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine A 29 Y old lady diagnosed as chronic HBV 3 years ago during her pregnancy, no treatment
More informationAASLD PRACTICE GUIDELINES Chronic Hepatitis B: Update 2009
AASLD PRACTICE GUIDELINES Chronic Hepatitis B: Update 2009 Anna S. F. Lok 1 and Brian J. McMahon 2 This guideline has been approved by the American Association for the Study of Liver Diseases and represents
More informationClinical Application of HBs quantification
Clinical Application of HBs quantification Hepatology on the Nile 2 Advances in Liver Disease 2014, "World Expert Review» Wednesday, September 24, 2014 Pr Tarik Asselah MD, PhD; Service d Hépatologie &
More informationManagement of Chronic Hepatitis B: 2012 Update
Management of Chronic Hepatitis B: 2012 Update Brian J McMahon MD, Liver Disease and Hepatitis Program Alaska Native Medical Center and Arctic Investigations Program, CDC Conflicts of Interest The Liver
More informationHIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
More informationAASLD PRACTICE GUIDELINES Chronic Hepatitis B
AASLD PRACTICE GUIDELINES Chronic Hepatitis B Anna S. F. Lok 1 and Brian J. McMahon 2 This guideline has been approved by the American Association for the Study of Liver Diseases and represents the position
More informationJoão Silva de Mendonça, MD, PhD Infectious Diseases Service Hospital do Servidor Público Estadual São Paulo - Brazil
Brazilian Ministry of Health, Brazilian Society of Hepatology PAHO, Viral Hepatitis Prevention Board PART III SESSION 9 Prevention and control of Viral Hepatitis in Brazil HEPATITIS IN SPECIAL RISK GROUPS/
More informationThe Natural History of Chronic Hepatitis B Virus Infection
The Natural History of Chronic Hepatitis B Virus Infection Brian J. McMahon, M.D. 1 ABSTRACT Three stages of chronic hepatitis B virus (HBV) infection are recognized: the immune tolerant phase, the chronic
More informationThe availability of newer antiviral agents, as
TREATMENT OF HEPATITIS B VIRUS INFECTION * Norman L. Sussman, MD ABSTRACT In treating chronic hepatitis B virus (HBV) infection, the primary goal of therapy is to achieve sustained suppression of HBV replication,
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationHCV Treatment Failure
بسم االله الرحمن الرحيم HCV Treatment Failure Gamal Esmat PROF.OF HEPATOLOGY&TROPICAL MEDICINE CAIRO UNIVERSITY Director of Viral Hepatitis Treatment Centers (VHTCs( VHTCs) MOH-EGYPT www.gamalesmat.com
More informationLA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
More informationChronic hepatitis B (CHB) remains an important public SPECIAL REPORT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1315 1341 SPECIAL REPORT A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update EMMET B. KEEFFE,*
More informationPREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
More informationWhen an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
More informationVirology. Behandlung der Hepatitis B. HBV Genome. HBV life cycle. HBV Genotypes. Natural History. 8 genotypes: A, B, C, D, E, F, G, H
Virology Behandlung der Hepatitis B Markus Heim Universitätsspital Basel 1 2 HBV Genome HBV life cycle 3 4 HBV Genotypes Natural History 8 genotypes: A, B, C, D, E, F, G, H genotypes A and D are prevalent
More informationHEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
More informationHIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations
HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic
More informationEpidemiology of HCV and HIV/HCV Infection in Guangzhou, China. Title. Charles Wang, M.D.
Epidemiology of HCV and HIV/HCV Infection in Guangzhou, China Title Charles Wang, M.D. Background Hepatitis C infects 170 million worldwide & 3 million Chinese HIV infects 33.3 million worldwide & 740,000
More informationTreatment of Acute Hepatitis C
Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Acute Hepatitis C Michael P. Manns, Andrej Potthoff, Elmar Jaeckel, Heiner Wedemeyer Hepatitis C Virus (HCV) infection is a common
More informationHepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationTreatment of Hepatitis B
Treatment of Hepatitis B Paul Y Kwo, MD Professor of Medicine Gastroenterology/Hepatology Division Medical Director, Liver Transplantation Indiana University Health Indiana University School of Medicine
More informationHepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
More informationPost AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in
Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull
More informationHBV DNA < monitoring interferon Rx
Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute
More information2015 Outpatient Chronic Hepatitis B Management
2015 Outpatient Chronic Hepatitis B Management Hepatitis B Hepatitis B Info 70% of acute infections are subclinical More severe symptoms when in addition to other liver disease Fulminant Hepatitis
More informationHBV screening and management in HIV-infected children and adolescents
HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally
More informationHEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis
HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School
More informationHepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm?
Hepatitis C David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham Substance Misuse Treatment in the West Midlands. How can we reduce harm? Birmingham October 19 th 2007 infection HCV Natural History
More informationCASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma
CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma Occult HBV Infection: Assessment and Clinical Significance D. Lorne Tyrrell Director, Li Ka Shing Institute of Virology University of Alberta
More informationRobert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
More informationCurrent Opinion in Hepatitis C Treatment
White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University
More informationSafety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B
Safety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B Anna S. F. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology University
More informationHepatitis C Treatment: Tailoring Therapy To Maximize Response
PRINTER-FRIENDLY VERSION AT GASTROENDONEWS.COM Hepatitis C Treatment: Tailoring Therapy To Maximize Response PATRICK J. AMAR, MD Department of Gastroenterology and Hepatology Holy Cross Medical Group Fort
More informationEpidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid
Epidemiology of Hepatitis C Infection Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid Worldwide Prevalence of Hepatitis C 10% No data available WHO.
More informationPERINATAL AND CHILDHOOD HEPATITIS.. WHAT ABOUT THE CHILDREN?
PERINATAL AND CHILDHOOD HEPATITIS.. WHAT ABOUT THE CHILDREN? John T. Stutts, MD, MPH University of Louisville School of Medicine Department of Pediatrics Division of Pediatric Gastroenterology, Hepatology
More informationCASG HBV Study Richard B. Pollard, MD David M. Asmuth, MD Division of Infectious Diseases University of California Davis Medical Center Sacramento, CA
CASG HBV Study Richard B. Pollard, MD David M. Asmuth, MD Division of Infectious Diseases University of California Davis Medical Center Sacramento, CA Characteristics of HBV DNA Hepadnavirus Reverse transcriptase
More informationPlacing Nation on the Path Toward the Elimination of Hepatitis C
Placing Nation on the Path Toward the Elimination of Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Division of Viral Hepatitis National Center for
More informationRecommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965
Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center
More informationEASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version)
Journal of Hepatology 38 (2003) 533 540 Special article EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version) The EASL Jury*
More informationDisclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
More informationHepatitis Update 2013. Brendan M. McGuire, MD UAB Liver Center
Hepatitis Update 2013 Brendan M. McGuire, MD UAB Liver Center Introduction Hepatitis - Inflammation of the liver Five types A B C D E Characteristics of Hepatitis Viruses Virus Genome Family Major mode
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationPURPOSE: To define the criteria to be used to determine the medical necessity of antiviral therapy in the treatment of Chronic Hepatitis B.
COVENTRY Health Care Guidelines for Hepatitis B Therapy SUBJECT: Chronic Hepatitis B Therapy: a. Interferons - Intron A (interferon alfa-2b) and Pegasys (peginterferon alfa-2a) b. Nucleoside analogues
More informationAASLD PRACTICE GUIDELINE UPDATE Chronic Hepatitis B: Update 2009
AASLD PRACTICE GUIDELINE UPDATE Chronic Hepatitis B: Update 2009 Anna S. F. Lok 1 and Brian J. McMahon 2 The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines
More information1.1.2 Amend the that the Special Authority relating to tenofovir for use in pregnancy for postpartum care;
Anti-Infective Subcommittee of PTAC Meeting held 1 March 2012 (minutes for web publishing) Anti-Infective Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationHepatitis C: Epidemiology, Transmission, and Screening. Jennifer Price, MD Assistant Professor of Medicine University of California San Francisco
Activity Code FA376 Hepatitis C: Epidemiology, Transmission, and Screening Jennifer Price, MD Assistant Professor of Medicine University of California San Francisco Learning Objectives Upon completion
More informationDiagnosi e terapia delle epatiti croniche virali
Diagnosi e terapia delle epatiti croniche virali Fabrizio Magnolfi Direttore della Struttura Complessa di Gastroenterologia Ospedale S. Donato - Arezzo Caso clinico 1 Fattori eziologici delle Epatopatie
More informationThe Epidemiology of Hepatitis A, B, and C
The Epidemiology of Hepatitis A, B, and C Jamie Berkes M.D. University of Illinois at Chicago jberkes@uic.edu Epidemiology: Definitions The study of the incidence and prevalence of diseases in large populations
More informationHCV treatment today: pegylated interferons and ribavirin
HCV treatment today: pegylated interferons and ribavirin Other special patient populations Patients with cirrhosis Higher SVR rates are achieved in patients without cirrhosis Patients without bridging
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationEmerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV
More informationHepatitis C Class Review
Hepatitis C Class Review Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January
More informationPrior Authorization Policy
Prior Authorization Policy http://www.paramounthealthcare.com/providers Ribavirin Rebetol (ribavirin capsule or oral solution) Copegus (ribavirin tablet), Moderiba (ribavirin tablet), Ribasphere (ribavirin
More informationHCV and Diabetes. Francesco Negro. University Hospital of Geneva, Switzerland HepDART, Tuesday, December 10 th, 2013, Big Island, HI
HCV and Diabetes Francesco Negro University Hospital of Geneva, Switzerland HepDART, Tuesday, December 10 th, 2013, Big Island, HI Host genes Sedentary lifestyle HCV Drugs Environmental toxins (bisphenol
More informationLamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine
Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease From : New England Journal of Medicine Volume 351:1521-1531, Number 15, Oct 7, 2004 馬 偕 紀 念 醫 院 一 般 內 科, 肝 膽 腸 胃 科 新 竹 分 院 陳 重
More informationPositive impact of HCV treatment initiation on health outcomes in injecting drug users
Positive impact of HCV treatment initiation on health outcomes in injecting drug users Perrine ROUX, PhD Substance Use Research Center, Columbia University, NY Inserm U912, SE4S, Marseille Introduction
More informationPHARMACY PRIOR AUTHORIZATION
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization
More informationThe natural history of chronic HBV infection
Hepatitis B Viral Factors in HBeAg-Negative Carriers with Persistently Normal Serum Alanine Aminotransferase Levels Chih-Lin Lin, 1* Li-Ying Liao, 1* Chun-Jen Liu, 2 Ming-Whei Yu, 3 Pei-Jer Chen, 2,4 Ming-Yang
More informationNew treatment options for HCV: implications for the Optimal Use of HCV Assays
New treatment options for HCV: implications for the Optimal Use of HCV Assays Hans Orlent Dept. of Gastroenterology & Hepatology AZ Sint Jan Brugge-Oostende, Brugge This program is supported by educational
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B
Journal of Hepatology 50 (2009) 227 242 www.elsevier.com/locate/jhep EASL Clinical Practice Guidelines: Management of chronic hepatitis B European Association for the Study of the Liver * Keywords: Hepatitis
More informationTreatment Strategies of Hepatitis B in China
Treatment Strategies of Hepatitis B in China Guangbi Yao MD Shanghai Jing-An Qu Central Hospital 200040 Characteristic features of CHB in China Huge amount of patients Infection during early life Maternal
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationManaging Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study
Managing Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study Case Prepared by Sinēad Sheils CNC Royal Prince Alfred Hospital, Sydney Friday 17 th May 2013 Nigel 63 yrs old caucasian male HCV
More informationStepwise Approach for Detecting, Evaluating, and Treating Chronic Hepatitis B Virus Infection
Stepwise Approach for Detecting, Evaluating, and Treating Chronic Hepatitis B Virus Infection Federal Bureau of Prisons Clinical Practice Guidelines January 20, 2011 Clinical guidelines are made available
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationEfficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients
Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of
More informationHepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
More informationManagement of Chronic Hepatitis B: Consensus Guidelines
Management of Chronic Hepatitis B: Consensus Guidelines Morris Sherman MD PhD 1, Stephen Shafran MD 2, Kelly Burak MD 3, Karen Doucette MD 2, Winnie Wong MD 2, Nigel Girgrah MD 1, Eric Yoshida MD 4, Eberhard
More informationHepatitis C and Liver Transplantation. Dinesh Ranjan, M.D. Professor of Surgery Director of Liver Transplantation University of Kentucky
Hepatitis C and Liver Transplantation Dinesh Ranjan, M.D. Professor of Surgery Director of Liver Transplantation University of Kentucky History Known as Non-A A Non-B B Hepatitis in 1974 HCV identified
More informationPrimary Care for Hepatitis B and C:
Primary Care for Hepatitis B and C: Clinical Tools for Efficient Management Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California, San Francisco Outline 1. Epidemiology of
More informationHepatitis C and pregnancy
Hepatitis C and pregnancy Assess HCV status at first visit Unknown HCV status If HCV + status based only on EIA +, order confirmatory RT-PCR Known HCV + status (RIBA or RT-PCR +) Hepatitis C Risk Factors
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationSupplementary Online Content
Supplementary Online Content Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving
More information12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS
HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE DISEASE 101 ONLINE CONFERENCE SARAH WENINGER, MPH VIRAL HEPATITIS.STD.HIV PREVENTION COORDINATOR DECEMBER 3, 2015 OBJECTIVES Describe the populations that should
More informationKY Hepatitis Connections
KY Hepatitis Connections Greetings partners and colleagues! March is here and spring is right around the corner. I have settled into my new role and have received input from many of you related to the
More informationScottish Medicines Consortium
Scottish Medicines Consortium peginterferon alfa-2a, 135 microgram/ml and 180 microgram/ml pre-filled injections of solution for subcutaneous injection (Pegasys ) No. (561/09) Roche Products Limited 10
More informationHepatitis C Vaccines: Are we making progress?
Hepatitis C Vaccines: Are we making progress? Second International Hepatitis Cure and Eradication Meeting. Vancouver November, 2015 Objectives: Review the need for a preventive vaccine in 2015. Identify
More informationAcute HCV was defined as (3 out of 4 within the preceding 4 months):
Christoph Boesecke, Patrick Ingiliz, Hans-Jürgen Stellbrink, Mark Nelson, Sanjay Bhagani, Marguerite Guiguet, Marc-Antoine Valantin, Thomas Reiberger, Martin Vogel, Jürgen K. Rockstroh, and the NEAT study
More informationMonth/Year of Review: March 2014 Date of Last Review: February 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationHEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015
CME ACCREDITED INTERACTIVE TRAINING SESSION: HEPATITIS C (HCV) @DDW 2015 LIVER DISEASE 905 891 1900 www.careeducation.ca info@careeducation.ca Community Academic Research Education @wearecare CME ACCREDITED
More informationOptimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?
Liver International ISSN 1478-3223 REVIEW ARTICLE Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy? Jorg Petersen 1 and Maura Dandri 2 1 IFI Institute at the Asklepios Klinik
More informationDosaggi Sierologici e Molecolari nelle Epatiti B e C METODI MOLECOLARI. Ombretta Turriziani Dipartimento di Medicina Molecolare
Dosaggi Sierologici e Molecolari nelle Epatiti B e C METODI MOLECOLARI Ombretta Turriziani Dipartimento di Medicina Molecolare Dosaggi Sierologici e Molecolari nelle Epatiti B e C Molecular Methods Key
More informationHepatitis C Virus Infection in Massachusetts: A tale of two epidemics
Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics Daniel Church, MPH Massachusetts Department of Public Health Bureau of Infectious Disease 1 Goals of presentation Provide an overview
More informationDr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor. Hepatology-2014
Dr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor Hepatology-2014 Other virus hepatitis Epstein-Barr vírus Cytomegalo vírus Herpes simplex vírus Coxsackie vírus Hepatitis B vírus Hepadnavírus,
More information